BDX — Becton, Dickinson and Company

Is BDX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Neutral As of August 19, 2026

Becton, Dickinson and Company (BDX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $187.60. The rating moved from Overbought to Neutral on August 19, 2026.

AI analysis

Becton, Dickinson and Company is a diversified medtech and life‑science supplier with stable cash flows, a strong installed base of consumables and recurring revenues, and exposure to diagnostic and bioscience end markets that should support demand. Near‑term sentiment has been mixed, but structural drivers — diagnostics procedure growth, adoption of automation/robotics, and continued demand for lab/CDMO services tied to biologics — provide potential revenue upside. Financial flexibility and steady capital returns support downside protection, although reimbursement headwinds, regulatory risks, competition, and supply‑chain cost pressure remain meaningful constraints. The outlook favors steady execution and selective growth from new product rollouts and labs/diagnostics strength; outcomes will hinge on margin recovery, adoption timing, and macro healthcare utilization trends.

Key factors

  • Diversified medtech and life‑science portfolio spanning devices, diagnostics and biosciences provides stable, recurring revenues and exposure to multiple end markets
  • Diagnostics and screening tailwinds (oncology, image‑guided procedures) support consumables and instrument demand over the medium term
  • Exposure to lab-supply and CDMO/CRO demand driven by biologics and synthetic biology trends that can lift volumes for certain BD segments
  • Strong cash flow generation and track record of capital returns (dividend and share repurchase) underpin shareholder returns
  • Ongoing product innovation and incremental upgrades (e.g., procedure navigation, automation) support modest pricing power and share gains
  • Relatively defensive profile amid mixed market sentiment, which can help preserve value during risk‑off periods

Risks

  • Reimbursement pressure and payer dynamics that can compress procedure volumes or payment rates for hospital/clinic customers
  • Regulatory approvals, recalls or litigation in high‑risk device categories could weigh on revenue and margins
  • Competitive pressure from other large medtech firms and specialized device players leading to price pressure or lost share
  • Supply‑chain disruptions or component cost inflation that erode margin recovery
  • Slower than expected adoption of new diagnostic/robotic workflows, delaying revenue upside
  • Short‑term negative social/media sentiment and headline risk could pressure near‑term stock performance

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for BDX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.